<DOC>
	<DOCNO>NCT00942240</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability repeat dose new investigational drug ( ACU-4429 ) healthy human subject .</brief_summary>
	<brief_title>Safety Tolerability Repeat Doses ACU-4429 Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>male female , 25 55 year age , inclusive within BMI range 19 32 kg/m2 Screening good health , determine clinically significant finding medical history , 12lead ECG , vital sign ; clinical laboratory evaluation ( include serum Chem20 [ fast least 10 hour ] , CBC differential platelet count , PT , INR , aPTT , UA ) within reference range test laboratory , unless deem clinically significant Investigator ; Males ( female partner male subject ) female must sterile , agree use approve contraceptive measure throughout study period 45 day End In House Study . able comprehend willing sign Informed Consent Form . significant history clinical manifestation significant metabolic , endocrine , allergic , dermatological , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , neurological , psychiatric disorder ( determined Investigator ) ; history significant hypersensitivity , intolerance , allergy drug compound , food , substance , unless approve Investigator ; history stomach intestinal surgery resection would potentially alter absorption and/or excretion orally administer drug , except appendectomy , hernia repair , and/or cholecystectomy allow ; history presence abnormal ECG , , Investigator 's opinion , clinically significant ; participation investigational study drug trial receipt investigational study drug occur within 30 day prior Checkin ; Is currently use , recently receive treatment medication disallow Protocol .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>